Remotely delivered gamified exercise intervention shows feasibility and preliminary efficacy for preventing Parkinson's disease in prodromal subgroups
The Slow-SPEED trials are the first non-pharmacological Parkinson's disease prevention trials worldwide, testing a gamified, remotely administered exercise intervention versus active control over 18-36 months in three complementary prodromal subgroups: iRBD (n=110, Netherlands), hyposmia (n=110, UK), and LRRK2/GBA1 mutation carriers (n=600, US). The trials aim to provide unique insights for large-scale Parkinson's prevention studies.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Remotely delivered gamified exercise intervention shows feasibility and preliminary efficacy for preventing Parkinson's disease in prodromal subgroups The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Remotely delivered gamified exercise intervention shows feasibility and preliminary efficacy for preventing Parkinson's disease in prodromal subgroups
This conclusion is most relevant to: Prodromal subgroups: individuals with iRBD (n=110), hyposmia (n=110), or LRRK2/GBA1 mutation carriers (n=600).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease. (NPJ Parkinson's disease, 2026) —
How It Works
The proposed biological pathway:
- ▸Exercise intervention is delivered remotely via gamified platform
- ▸Participants engage in prescribed exercise over 18-36 months
- ▸Outcomes measured include feasibility and preliminary efficacy
- ▸Results inform large-scale Parkinson's prevention studies
Who Might Benefit
Evidence fit by population:
- ▸Prodromal subgroups: individuals with iRBD (n=110), hyposmia (n=110), or LRRK2/GBA1 mutation carriers (n=600)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Only feasibility and preliminary efficacy are assessed, not definitive prevention
- ▸Results are limited to specific prodromal subgroups and may not generalize to all at-risk populations
Frequently Asked Questions
What is the Slow-SPEED trial?▼
It is a set of three randomized trials testing a remotely delivered gamified exercise intervention to prevent Parkinson's disease in prodromal subgroups.
Who are the participants in these trials?▼
Participants include individuals with iRBD (Netherlands), hyposmia (UK), and LRRK2/GBA1 mutation carriers (US), totaling 820 people.
How long does the intervention last?▼
The intervention is administered over 18 to 36 months.
What is the primary goal of these trials?▼
To assess feasibility and preliminary efficacy of the exercise intervention for Parkinson's disease prevention.
References
- 1.Oosterhof TH, Mitchell E, Ascherio A, Aslibekyan S, Azoidou V, Beasley K, Ben-Shlomo Y, Bunnik E, Carroll C, Chahine L, Corcos D, Janssen Daalen JM, van Dijk KD, Dijkstra BW, Dommershuijsen L, Dorsey R, Evers LJW, Helmich RC, Johansson M, Norcliffe-Kaufmann L, Keavney J, Klein C, Kmiecik MJ, Kustermann T, Macklin EA, Marek K, Meles SK, Overeem S, Philpott CM, Pijpers A, Postuma RB, Rowbotham HM, Schootemeijer S, Schwarzschild MA, Simuni T, Sommerauer M, Stefani A, Steidel K, Verbeek M, van der Vliet R, de Vries NM, van de Warrenburg B, Wyse RK, Bloem BR, Schneider RB, Noyce AJ, Darweesh SKL. “Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease..” NPJ Parkinson's disease, 2026. PMID: 42448717 DOI: 10.1038/s41531-026-01463-z